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Abstract
Background: Cardiovascular Magnetic Resonance (CMR) is increasingly used in daily clinical
practice. However, little is known about its clinical utility such as image quality, safety and impact
on patient management. In addition, there is limited information about the potential of CMR to
acquire prognostic information.
Methods: The European Cardiovascular Magnetic Resonance Registry (EuroCMR Registry) will
consist of two parts: 1) Multicenter registry with consecutive enrolment of patients scanned in all
participating European CMR centres using web based online case record forms. 2) Prospective
clinical follow up of patients with suspected coronary artery disease (CAD) and hypertrophic
cardiomyopathy (HCM) every 12 months after enrolment to assess prognostic data.
Conclusion: The EuroCMR Registry offers an opportunity to provide information about the
clinical utility of routine CMR in a large number of cases and a diverse population. Furthermore it
has the potential to gather information about the prognostic value of CMR in specific patient
populations.
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Cardiovascular disease is the major cause of mortality and
morbidity in the United States and in Europe. Cardiac
imaging is an integral part of the evaluation and manage-
ment of patients with known or suspected cardiovascular
disease. Echocardiography and single photon emission
computed tomography are well-established imaging tech-
niques to diagnose cardiovascular diseases and to provide
prognostic information. Cardiovascular Magnetic Reso-
nance (CMR) is also established in many sites, but its clin-
ical value regarding impact on decision-making and
patient safety is not well understood. Like traditional tech-
niques, CMR can assess cardiac anatomy, quantify ven-
tricular and valvular function, as well as identify areas of
necrosis, scarring and ischemia. There is an increasing
body of evidence that CMR is superior to traditional imag-
ing techniques due to the fact that it offers a higher spatial
resolution and the unique ability of tissue characteriza-
tion [1-3]. Consequently, the use of CMR in daily clinical
routine has rapidly grown in recent years. However, there
is very limited knowledge of its clinical utility, impact and
safety. The EuroCMR registry provides the unique oppor-
tunity to acquire data on the prognostic impact of CMR
studies performed in a real-life scenario. To address ques-
tions of clinical utility, impact, safety and prognostic
value, the EuroCMR Registry consists of two parts: 1) A
documentation of image quality, safety, and impact on
patient management in a large number of cases to assess
the clinical utility of CMR in daily clinical routine. 2) A
prospective clinical follow up of patients with suspected
coronary artery (CAD) disease and hypertrophic cardio-
myopathy (HCM) to assess prognostic data.
Methods
Study design
The EuroCMR Registry consists of two parts: 1) Multi-
center registry with consecutive enrolment of patients
scanned in all participating CMR centres. Indications for
CMR had to be according to the SCMR consensus appro-
priateness criteria for CMR [4], and all procedures must be
performed in compliance with the standardised SCMR
recommended protocols. 2) Prospective clinical follow up
of patients with suspected coronary artery disease and
hypertrophic cardiomyopathy every 12 months after
enrolment to assess prognostic data. The study is to be
approved by local institutional review boards and all
patients will be asked for informed consent.
Study population
1) Multicenter registry: The registry will include consecu-
tive patients who undergo CMR in one of the participating
sites. The only exclusion criteria are contraindications for
CMR.
2) Prospective clinical follow up: Participating centres are
required to enrol consecutive patients in at least one of the
specific protocols. Inclusion criteria for the two specific
protocols are as follows:
A) Suspected-CAD: Patients with suspected coronary
artery disease undergoing a combined CMR protocol
including evaluation of left ventricular function,
assessment of myocardial ischemia by adenosine
stress perfusion or high-dose dobutamine CMR, as
well as detection of myocardial infarction using late
gadolinium enhanced CMR.
B) HCM-SCD: Patients with hypertrophic cardiomy-
opathy undergoing a combined CMR protocol includ-
ing left ventricular function, rest perfusion, and
detection of myocardial scarring by late gadolinium
enhanced CMR. The diagnosis of hypertrophic cardio-
myopathy is based on the demonstration of a hyper-
trophied, non-dilated left ventricle (wall thickness of
at least 15 mm in adults or the equivalent relative to
body-surface area in children) in the absence of
another cardiac or systemic disease capable of produc-
ing a similar degree of hypertrophy. In adult relatives
of the patients with hypertrophic cardiomyopathy, a
wall thickness of 13 mm or more will be considered a
criterion for diagnosis.
Additional exclusion criteria for the two specific protocols
are as follows:
A) Suspected-CAD: Absence of patient informed con-
sent, known CAD by invasive coronary angiography or
previous myocardial infarction.
B) HCM-SCD: Absence of patient informed consent,
known CAD by invasive coronary angiography or pre-
vious myocardial infarction, left ventricular hypertro-
phy of other causes (e.g. hypertension, valvular heart
disease).
In addition, the EuroCMR registry is open to new specific
protocols to be added and operated by interested
researchers. Thus, the investigators of the EuroCMR regis-
try would very much like to encourage scientists in the
field of imaging to submit a proposal for additional new
specific protocols to the next registry steering committee
meetings http://www.eurocmr-registry.com, available
shortly, or http://www.escardio.org/communities/Work
ing-Groups/eurocmr/Pages/welcome.aspx).
Variables and definitions
Electronic case record forms will be used. All variables
assessed in the electronic case record form are pre-defined,
and will be collected directly from the patients, and/orPage 2 of 12
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data, patient's history, indication for CMR, CMR proce-
dural parameter, results of CMR, complications, and the
impact of the CMR procedure on the patient's clinical
management (figures 1 and 2). Most fields are self-explan-
atory; all other fields are defined in the appendix of this
manuscript, and are in agreement with recently published
key data elements and definitions for cardiac imaging [5].
In order to assess the clinical utility of routine CMR we
will document 1) image quality, 2) safety of the procedure
and 3) the impact on patient management.
1) To address image quality, studies will be graded in
non-diagnostic, moderate but diagnostic, and good
quality. A non-diagnostic study does not allow to
answer the question the CMR was ordered for. A study
will be graded as moderate if the images allow to
answer the question the CMR was ordered for, but
findings remain questionable due to artefacts. Studies
are graded as good if the images are of good quality
without artefacts allowing to provide a complete
answer to the question the CMR was ordered for.
2) In order to report the safety of CMR in clinical rou-
tine, complications of the procedure will be docu-
mented. Complications of CMR are defined as severe
complications in the setting of death, resuscitation, or
any other condition related to the CMR procedure that
required monitoring as an inpatient for at least one
night after the CMR scan. Mild complications are
defined as any complications related to the CMR study
not fulfilling the criteria for severe complication.
3) In order to evaluate the impact of CMR on patient
management, it will be reported if the CMR scan
directly results in a new diagnosis or initiates a direct
therapeutic consequence, such as a change in medica-
tion, ordering an invasive procedure, hospital admis-
sion or discharge.
Additional information will be collected for the patients
included in the specific protocols. The cardiovascular risk
profile for patients enrolled in the specific protocol "Sus-
pected CAD" will be assessed as shown in figure 3. Wall
motion and scar burden will be read in a 17-segment
model [6]. For patients included in the specific protocol
"HCM-SCD" traditional risk factors for sudden cardiac
death in patients with HCM will be reported according to
figure 4. Wall motion and scar burden will be read in a 17-
segment model [6].
Follow up
A clinical follow up will be performed and/or coordinated
by the "Institut für Herzinfarktforschung" for all patients
enrolled in specific protocols (Suspected-CAD, HCM-
SCD) every 12 months after enrolment. Follow ups will be
done by standardized telephone interviews. In case of no
contact, government registration offices will be asked for
new addresses of patient, or cases of death. In non-Ger-
man speaking countries one local key person appointed
by the steering committee that may assist the institute per-
forming the follow up. The endpoint that occurs first is
included in the analysis. Fatal endpoints, non-fatal end-
points, as well as procedures after enrolment will be
assessed (figure 5).
Data management
All data will be prospectively collected by trained person-
nel, manually entered in online case record forms based
on database elements provided by the "Institut für Her-
zinfarktforschung", University of Heidelberg, Germany
http://www.herzinfarktforschung.de/Projekte/RegisterI/
EuroCMR.html via a SSL-secured internet connection, and
stored on a central server. Each participating centre will
appoint a senior cardiologist or radiologist as local inves-
tigator responsible for the data quality of each individual
patient entered in the registry. The local investigator has
either to be SCMR level 3 trained, EuroCMR certified, or
licensed for CMR by the local chamber of physicians. A
plausibility check will directly carried out after submitting
the data to avoid further queries as far as possible. For
quality control purposes benchmarking reports will be
made available to the local investigators of all participat-
ing centres on a regular basis. The reports will be compiled
individually for each participating centre comparing all
data of the centre with those of all other centres. Data col-
lection and management will be approved by local ethics
committees.
Benchmarking reports
Benchmarking reports will be made available to the par-
ticipating centres on a regular basis. The report will be
compiled individually for each participating centre and
compares the data of the centre with those of the other
centres. The collected data will be evaluated in regard of
characteristics, therapy and clinical course of the included
patients.
Quality control
All participating centres have to provide the complete
CMR studies of 10% of their patients included selected at
random by the central database server. Centres may either
upload DICOM images to the central image storage sys-
tem (WEBPAX, HeartIt, Durham, USA), or sent DICOM
CD's to the institute. Members of the steering committee
will evaluate all provided cases in consensus read. If nec-
essary, participating centres will be visited by members of
the steering committee to address potential quality prob-
lems. In addition, a sample of participating centresPage 3 of 12
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Baseline characteristics part one - Electronic case record forms to assess baseline characteristics of all enrolled patients and CMR procedural parametersFigure 1
Baseline characteristics part one - Electronic case record forms to assess baseline characteristics of all 
enrolled patients and CMR procedural parameters.
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Baseline characteristics part two - Electronic case record forms to report the results, complications and 
planed procedures after the CMR scan.
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selected for monitoring including source data verification,
as well as the completeness of written informed consents.
Statistics
Since the objectives of this registry are descriptive in
nature, no formal hypothesis testing will be done. Abso-
lute numbers and percentages will be computed to
describe the patient population. Medians (with quartiles)
or means (with standard deviation) will be computed as
appropriate. Categorical values will be compared by chi-
square test and continuous variables will be compared by
two-tailed Wilcoxon rank sum test. P-values < 0.05 were
considered significant. All p-values will be results of two-
tailed tests. The tests will be performed using the SAS© sta-
tistical package, version 9.1 (SAS, Cary, North Carolina).
In the specific protocol "Suspected-CAD" the event rates
and corresponding 95% confidence intervals (CI) during
follow up will be estimated for prespecified subgroups
defined by result of CMR. Additionally regression models
will be assumed to identify independent risk factors and
for calculation of odds ratios. In the specific protocol
"HCM-SCD" the event rates and corresponding 95% con-
fidence intervals (CI) during follow up will be estimated
for prespecified subgroups defined by detected scar bur-
den. Additionally regression models will be assumed to
evaluate CMR parameters such as scar burden as inde-
pendent risk factors.
Assuming a mortality rate of 3% during the first year after
CMR in both specific protocols and a target accuracy
(range of CI) lower than 2% of the estimated event rate,
the sample size must exceed 1,120 patients in both proto-
cols. This assures that the accuracy of subgroups represent-
ing 25% of all patients in both specific protocols will be
lower than 4%. In order to assure an accuracy lower than
2% (instead of 4%), the sample size would need to exceed
4,450 patients.
Discussion
The EuroCMR Registry is the first dataset to assess the clin-
ical utility of routine CMR in a large number of cases in an
interdisciplinary multi-centre and multi-vendor setting.
The registry will provide the unique opportunity to
Specific protocol #1: Suspected-CAD - Electronic case record forms to document the cardiovascular risk profile for patients enrolled in he specific protocol "Suspect d CAD"Figur 3
Specific protocol #1: Suspected-CAD - Electronic case record forms to document the cardiovascular risk pro-
file for patients enrolled in the specific protocol "Suspected CAD".Page 6 of 12
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CMR studies performed in the daily clinical routine. The
EuroCMR Registry will give us an insight into the clinical
performance of CMR in a broad spectrum of practices of
varying size and among operators of varying experience.
In addition, the EuroCMR Registry will evaluate if CMR is
able to provide prognostic information by focusing on
two specific patient groups, suspected CAD and HCM. The
confirmation of improved outcomes attributable to cardi-
ovascular imaging is particularly challenging because of
the complex interplay of patient characteristics and treat-
ment strategies, including the substantial variability in
therapeutic care patterns after cardiac imaging, and there-
fore requires a large number of subjects.
A registry offers the advantage to collect data prospectively
in a real-life scenario as opposed to a randomized control-
led trial. However, it is important to point out that the
EuroCMR Registry is subject to the intrinsic limitations of
every registry, i.e. the data quality is dependent upon the
completeness of reporting and accuracy of the data.
In the future it will be important to assess quality, and fur-
ther improve quality of CMR imaging in clinical routine.
In the recent years there has been increasing concern that
less attention has been focused on quality in cardiac imag-
ing in general than other areas of cardiovascular medicine
[7]. As pointed out by the Past President of the American
College of Cardiology, Pamela Douglas, "the striking
growth in the use of cardiovascular diagnostic imaging
has been accompanied by a frustrating combination of
inconsistent usage, lack of rigorous controls, and little
measurable impact on outcomes" [8]. Consequently, sev-
eral authorities have called for efforts to improve quality
in imaging. For example, since "ordering the right test for
the right patient is an important component of quality in
imaging" [8] novel Appropriateness Criteria have been
Specific protocol #2: HCM-SCD - Electronic case record forms to determine the traditional risk factors for sudden cardiac death and CMR findings in patients with HCM enrolled in the specific protocol specific protocol "HCM-SCD"Figure 4
Specific protocol #2: HCM-SCD - Electronic case record forms to determine the traditional risk factors for 
sudden cardiac death and CMR findings in patients with HCM enrolled in the specific protocol specific protocol 
"HCM-SCD".Page 7 of 12
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European Society of Cardiology for several imaging
modalities including CMR [4,9]. The EuroCMR Registry
may be a first step to provide insight if CMR is used
according to the novel Appropriateness Criteria. In the
future it will be important to not only evaluate if CMR can
predict outcome, but also to assess if undergoing CMR
and a subsequent change in patient management based
on the study findings has any measurable impact on out-
come.
Conclusion
The EuroCMR Registry offers the opportunity to assess the
clinical utility and to define the future role of CMR. The
EuroCMR Registry also may serve as a tool to assess qual-
ity and further improve quality of CMR with subsequent
better patient care.
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Appendix
List of definitions used in the EuroCMR Registry
• Heart rate: heart rate measured during CMR scan.
• Ventricular extrasystole: includes ventricular extra-
systoles during CMR image acquisition.
• Cardiac arrest: abrupt cessation of normal circula-
tion of the blood.
• Allergic shock: serious allergic reaction that is rapid
in onset (over minutes to 24 hours after injection of
contrast agent), involving the skin, mucosal tissue, or
both and evidence of respiratory compromise or
reduced blood pressure (systolic BP of less than 90
mmHg or greater than 30% decrease from that per-
son's baseline) or persistent gastrointestinal symp-
toms.
• Allergy to contrast agent: acute onset of an illness
(over minutes to 24 hours after injection of contrast
agent) involving the skin, mucosal tissue, or both (eg,
generalized hives, pruritus or flushing).
• Non-sustained ventricular tachycardia: monomor-
phic or polymorphic tachycardia with regard to QRS
or electrocardiographic polarity, amplitude, and mor-
phology, with a mean cycle length of less than 240
msec.
• Ventricular fibrillation: Rapid, more than 300 bpm/
200 ms (cycle length 180 ms or less), grossly irregular
ventricular rhythm with marked variability in QRS
cycle length, morphology and amplitude.
• Ventricular flutter: A regular (cycle length variability
30 ms or less) ventricular arrhythmia approximately
300 bpm (cycle length -200 ms) with a monomorphic
appearance; no isoelectric interval between QRS com-
plexes.
• Local complications at the iv infusion site include
local swelling and/or erythema and prolonged pain at
injection site.
• Hypertension: defined as a blood pressure >140/90
mmHg for patients without diabetes or chronic kidney
disease, or prior documentation of blood pressure
>130/80 mmHg on at least two occasions in patients
with diabetes or chronic kidney disease.
• Controlled hypertension: Patient takes currently
antihypertensive agent(s) and blood pressure is at
goal.
• Uncontrolled hypertension: Patient takes antihyper-
tensive agent(s) and blood pressure is not at goal.
• Dyslipidemia: patient has a history of dyslipidemia
diagnosed and/or treated by a physician. Or: Total
cholesterol greater than 200 mg/dl (5.18 mmol/l), or
Low-density lipoprotein (LDL) greater than or equal
to 130 mg/dl (3.37 mmol/l)or High-density lipopro-
tein (HDL) less than 40 mg/dl (1.04 mmol/l) in men
and less than 50 mg/dl (1.30 mmol/l) in women, or
currently on antilipidemic treatment.
• Diabetes mellitus: refers to any history or current
diabetes (diagnosed by at least 2 fasting glucose meas-
ures >7 mmol/L or >126 mg/dl), or a elevated non-
fasting glucose level, treated or not.
• Smoker: this includes cigarettes, cigar, tobacco chew,
etc. No: subject has never smoked. Current: use of
tobacco within 1 month of this study. Previous: use of
tobacco greater than 6 months prior to this study.
• Family history of prior CAD: any first-degree rela-
tives (parents, siblings, children) who have had any of
the following at age less than 55 years: 1. angina, 2.
myocardial infarction (MI), 3. coronary artery bypass
graft (CABG), 4. percutaneous coronary intervention
(PCI), or 5. sudden cardiac death without obvious
cause.
• Blood pressure: systolic and diastolic blood pressure
should be measured in a seated position after at least
5 minutes of rest and at the date the CMR is per-
formed.
• Total cholesterol: most recent cholesterol measure-
ment (mg/dl) in medical record up to 6 months prior
to CMR study.Page 9 of 12
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(mg/dl) in medical record up to 6 months prior to
CMR study.
• HDL cholesterol: most recent HDL measurement
(mg/dl) in medical record up to 6 months prior to
CMR study.
• Family history of HCM: any first-degree relatives
(parents, siblings, children) who was diagnosed with
HCM
• Family history of premature sudden cardiac death:
unexpected arrest of presumed cardiac origin that
could be interpreted as being cardiac in origin in any
first-degree relatives (parents, siblings, children).
• Unexplained syncope: one or more episodes of
unexplained loss of consciousness
• Spontaneous ventricular tachycardia: regular (mon-
omorphic) or irregular (polymorphic) tachycardia
with regard to QRS or electrocardiographic polarity,
amplitude, and morphology, with a mean cycle length
of more than 240 msec
• Abnormal exercise blood pressure: systolic blood
pressure that fails to increase >20 mm HG during max-
imal treadmill exercise.
• Outflow tract obstruction: resting peak outflow tract
gradient > 30 mmHg by echo.
• Maximal pressure gradient (echo) at exercise: highest
gradient measure by pulsed Doppler studies.
• Maximal wall thickness: end-diastolic thickness of
the thickest wall measured in a true cross sectional
view in the 17 segment model.
• LA dimension: dimension measured in the paraster-
nal long-axis view (4 chamber) similar to echo.
• Fatal endpoints:
1. Sudden cardiac death: unexpected arrest of pre-
sumed cardiac origin within one hour after onset
of any symptoms that could be interpreted as
being cardiac in origin (e.g. death after 30 minutes
of angina). If arrest occurs between 1 and 24 hours
after onset of symptoms, classify as 'possible' sud-
den death.
2. Unwitnessed death: subject found deceased with
no history of new symptoms within the previous
72 hours.
3. Death within 28 days of cardiac arrest.
4. Death from myocardial infarction: death occur-
ring <28 days after MI.
5. Death from congestive heart failure: docu-
mented by the presence of signs of either right or
left ventricular failure or both on physical exam or
radiographic exam. The diagnosis should be con-
firmed by non-invasive or hemodynamic measure-
ments.
6. Death from stroke: neurologic symptoms com-
patible with stroke confirmed by a neurologist
prior to death. Or a focal neurologic defect that
persists ≥ 24 hours and is confirmed by either a
neurologist or by an imaging procedure prior to
death. Or confirmed by autopsy.
7. Death from other cardiovascular cause: include
aortic dissection, pulmonary embolism, death
from non-cardiovascular cause and death from
unknown cause.
• Non-fatal endpoints:
1. Aborted sudden cardiac death: resuscitation
after cardiac arrest defined as performance of the
physical act of cardioversion or CPR in a patient
who remains alive 28 days later.
2. ICD shock: Stored data will be analyzed to clas-
sify the arrhythmias responsible for precipitating
defibrillator discharges, according to the following
definitions:
a) Nonsustained tachycardia: see definition
above.
b) Nonsustained ventricular tachyarrhythmias
that do not activate device therapy are to be
excluded.
c) Appropriate ICD shocks: defibrillator dis-
charges that will be considered appropriate
include automatic defibrillation shocks or pro-
grammed antitachycardia overdrive pacing
triggered by ventricular tachycardia or fibrilla-
tion and documented by stored intracardiac
electrocardiographic or cycle-length data.Page 10 of 12
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defibrillators without the capacity to store elec-
trocardiographic data, discharges will be
judged to be appropriate on the basis of clinical
findings that strongly suggested the presence of
ventricular arrhythmia (i.e., symptoms such as
presyncope or syncope immediately before the
discharge and the absence of these symptoms
immediately afterward).
e) Inappropriate ICD shocks: discharges trig-
gered by a rapid ventricular rate exceeding the
programmed threshold rate as a consequence
of supraventricular tachycardia, exercise-
related sinus tachycardia, or a malfunction of
the device.
f) For patients with defibrillators that do not
store electrocardiographic data, discharges will
be defined as inappropriate if they are not pre-
ceded by symptoms, if circumstances suggested
the presence of sinus tachycardia due to emo-
tional or physical stress, or if there was a mal-
function of the device.
g) Indeterminate ICD shocks: in patients where
the there is insufficient data to determine
whether an ICD shock is or is not appropriate,
the ICD shock will be coded as indeterminate.
3. Non fatal myocardial infarction: typical rise and
fall of troponin or CK-MB biomarkers of myocar-
dial necrosis with at least one of the following:
ischemic symptoms, development of pathologic
Q-waves on the ECG or ECG changes indicative of
ischemia (ST elevation or depression) with angio-
graphic evidence of CAD.
4. Non fatal stroke: neurologic symptoms compat-
ible with the diagnosis of stroke as confirmed by
neurologist or a focal neurologic defect that per-
sists for ≥ 24 hours and is confirmed by a neurolo-
gist or an imaging study.
5. Syncope: one or more episodes of unexplained
loss of consciousness.
• NYHA:
1. Class I: patients with cardiac disease but without
resulting limitations of physical activity. Ordinary
physical activity does not cause undue fatigue, pal-
pitation, or dyspnea.
2. Class II: patients with cardiac disease resulting in
slight limitation of physical activity. They are com-
fortable at rest. Ordinary physical activity results in
fatigue, palpitation, or dyspnea.
3. Class III: patients with cardiac disease resulting
in marked limitation of physical activity. They are
comfortable at rest. Less than ordinary activity
causes fatigue, palpitation, or dyspnea.
4. Class IV: patients with cardiac disease resulting
in inability to carry on any physical activity with-
out discomfort. Symptoms are present even at rest
or minimal exertion.
• CCS:
1. Class 0: Asymptomatic. No angina.
2. Class I: Ordinary physical activity (e.g., walking
or climbing stairs) does not cause angina; angina
occurs with strenuous or rapid or prolonged exer-
tion at work or recreation.
3. Class II: Slight limitation of ordinary activity
(e.g., angina occurs walking or stair climbing after
meals, in cold, in wind, under emotional stress, or
only during the few hours after awakening; walk-
ing more than 2 blocks on the level or climbing
more than 1 flight of ordinary stairs at a normal
pace; and in normal conditions).
4. Class III: Marked limitation of ordinary activity
(e.g., angina occurs with walking 1 or 2 blocks on
the level or climbing 1 flight of stairs in normal
conditions and at a normal pace).
5. Class IV: Inability to perform any physical activ-
ity without discomfort; angina syndrome may be
present at rest.
• Procedures following enrolment:
1. Protocol "Suspected-CAD": percutaneous coro-
nary intervention (PCI) and coronary artery bypass
grafting (CABG), first performed procedure after
CMR, successful or not.
2. Protocol "HCM-SCD": ICD placement for pri-
mary or secondary prevention, pacemaker place-
ment for outflow tract obstruction, myectomy
(with or without another procedure), and alcohol
septal ablation.Page 11 of 12
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